Shahram Seyedin-Noor
@ShahramSN
Followers
2K
Following
6K
Media
167
Statuses
3K
founder @CivilizationVC | Venture Contrarian | 1st $ @omadahealth @ForesightDx @BillionToOneInc | 22 health tech + bio exits | 🧬 🌎 🕊️ | views my own
San Francisco
Joined July 2020
The answer is no. There are no data for BPC-157 and TB-500 peptides to establish efficacy or safety. Yet in contrast to lack of data, the promotion is boundless https://t.co/gaQ9wNKJe0 More in depth here https://t.co/syD4XOOCcK
28
58
331
"Dr. Chan, 40, a pediatrician, has said the organization sees its best return on investment from science. The philanthropy has reduced the size of grants it has given to other areas like education and housing but said it would not end that giving entirely." Mark Zuckerberg and
nytimes.com
The Chan Zuckerberg Initiative said its restructured organization, Biohub, would lead its focus on artificial intelligence and scientific research.
0
3
26
Once in a generation a founder comes along where extraordinary ambition is matched by exceptional ability. Where purpose and impact result from an innovation which will transform a field. In this case, two founders. Congrats to Oguzhan Atay (CEO) and David Tsao (CTO) for
forbes.com
Turkish immigrant Oguzhan Atay started the company in 2016 with a focus on prenatal testing. Now, he’s expanding to cancer tests.
2
3
26
Sad to see a center of bio innovation shut down, regardless of the politics surrounding it. I will point out that the @arcinstitute in the Bay Area is doing this the right way and is filled with absolutely phenomenal scientist. @genophoria @patrickc
Scoop: Arena BioWorks, the buzzy research institute that launched nearly two years ago with $500 million to support a decade of scientific R&D, is abruptly shutting down, the institute confirmed to @statnews. https://t.co/OGGhOxfNF9 W/@Jasonmmast
4
3
51
Even if pharma acquires ALL of the revenue generating biotech it would only cover half of the patent cliff just next year! So M&A has to go earlier and fast!
Tim Opler (@TimOpler ) leading a discussion on investment in biotech. Window is opening & shifting to earlier stage both for funding & M&A. Public markets in a unique state & will be for another 6-9 months. Lots of biotech M&A & generalist investors are back. #BioEurope25
2
12
66
For anyone who couldn't attend our live @SirenBio webinar last week: I got you! 🫶 Here is the recording on how to set up and lead a successful #CommunityInvestmentRound on @Wefunder! 🎬
🚀 Hey #founders and builders! Thinking about opening your own community investment round? We just dropped the full recording of our webinar where the @SirenBio team walks through how we approached - and successfully ran - our own community round. It’s not legal or financial
1
4
18
Tackle problems, not people. Negotiate your interests, not positions. Apologize if you made an error; never apologize otherwise.
0
1
3
Never argue with a man in a hoodie who says he’s fixing healthcare with AI. He’s already reached conclusions far beyond your facts.
4
2
16
Shame on you @Aetna for putting up this absurd barrier to limit a desperate cancer patient’s access to amivantanab, while pretending to have more oncology expertise than do this physician patient’s own oncologists, our guideline committees, and the @FDA. @DGlaucomflecken
From Dr. Bryant Lin, Stanford I'm living in insurance hell!!! 1) I am a Stage 4 Lung Cancer patient and advocate. 2) As a medical school Clinical Professor, I taught a class at Stanford anchored around my own case which was covered widely in the The New York Times, CBS Mornings,
0
6
16
Genomic variants in the LDL receptor are the big driver of atherosclerosis, but most were previously unclassified for their impact. Today @ScienceMagazine nearly all 17,000 variants (!) were assessed functionally, which markedly improves the diagnosis for familial high
13
128
489
#biotech is officially back.
The finger pointing in the Pfizer/Novo bidding war is priceless. (Can Bourla get Trump to step in? For a price, of course.) But with the Big Pharmas romping and stomping at the deal table, I have to wonder when we'll see a $20B+ buyout deal. Good for Metsera. Good for biotech.
0
1
3
It worked. Stem cells (mesenchymal) given to patients with a large heart attack reduced major adverse events in a randomized trial vs standard care https://t.co/ycKZKshxiX
13
141
639
Modern science can prove biosimilars are equivalent without costly, outdated, unnecessary clinical studies. My bill pushed the FDA to follow the evidence—and now they have. This reform cuts costs, not corners. Thanks to @DrMakaryFDA for his leadership in making this reform a
189
214
2K
Civilization is a woven fabric across cultures, time and geography. Technology and innovation don’t come from the “West” anymore than they come from the “East”. A student of history will know they come from all. I encourage people not to think in terms of “me”, or “you” or
1
1
7